PALO ALTO, Calif., Sept. 18, 2017 /PRNewswire/ -- Varian Medical
Systems (NYSE: VAR) today announced the newest release of its
treatment planning system, Eclipse 15.5. This new release has
received FDA 510(k) clearance, and incorporates several new
treatment capabilities that offer clinicians the ability to create
more precise treatment plans quickly. Eclipse 15.5 also provides
treatment planning support for Varian's HyperArc HDRT, a new
type of radiosurgery treatment.
Eclipse 15.5 features MCO, which allows clinicians to explore
what happens when different clinical criteria are varied; such as
the degree to which particular organs are spared versus coverage of
the targeted tumor. MCO leverages both RapidPlan™
and the existing optimization workflows to expedite finding the
optimal plan for a given patient with minimal trial and error
iterations.
For efficient treatment planning and automated delivery of
complex stereotactic radiosurgery, Eclipse 15.5 now supports
HyperArc. This new type of radiosurgery treatment is designed to
capitalize on the unique capabilities of Varian's
TrueBeam® and EDGE™ treatment platforms.
HyperArc treatments exploit specific capabilities of the platforms
to deliver more compact radiation doses that can fully saturate a
targeted tumor and "fall off" sharply outside the target zone,
minimizing and, where necessary, even eliminating dose to specific
organs requiring more protection.
To increase the speed of plan development, Eclipse 15.5 offers
Graphics Processing Unit (GPU) support. This enables clinicians to
utilize GPU technology to optimize and quickly calculate the dose
with Eclipse, including IMRT optimization and the intermediate dose
calculation within the optimization.
"With Eclipse 15.5 we have seen an instant improvement in plan
quality when using MCO, across a wide range of treatment sites,"
said Suzanne Currie, clinical
scientific lead at Beatson West of Scotland Cancer Centre. "We have
been able to reduce doses to organs at risk to levels that could
not have been envisaged before now, while at the same time tumour
coverage has been maintained or even improved. Even in this short
timeframe of using MCO, I would not want to plan without it."
"Eclipse 15.5 provides clinicians with powerful new tools to
quickly create optimized treatment plans that are unique to each
patient," said Ed Vertatschitsch,
vice president, global portfolio solutions, Varian Medical Systems.
"Additionally, the ability to utilize HyperArc for complex
stereotactic radiosurgery is a significant step forward in the
fight against cancer."
"It can typically take many hours to create treatment plans for
each patient," said James Kavanaugh,
instructor of Radiation Oncology and chief of affiliate
satellite medical physics services at Washington University School of Medicine in
St. Louis. "When we evaluated
about 160 patient treatment plans using the software, we found that
it could help us more efficiently explore clinical tradeoffs of
various treatment plans and improve the overall plan quality
for the majority of cases."
For more information on Eclipse 15.5, visit
http://www.varian.com/news/eclipse.
About Varian Medical Systems
Varian Medical Systems
focuses energy on saving lives and is the world's leading
manufacturer of medical devices and software for treating and
managing cancer. Headquartered in Palo
Alto, California, Varian employs approximately 6,600 people
around the world. For more information, visit
http://www.varian.com and follow @VarianMedSys on Twitter.
View original
content:http://www.prnewswire.com/news-releases/varian-expands-clinicians-cancer-fighting-toolkit-with-eclipse-155-300520690.html
SOURCE Varian Medical Systems